Medical/Pharmaceuticals
Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry
SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment ofJie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters inShanghai, China. Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and ...
2019-12-18 00:00
1971
MoA Technology implements CDD Vault to manage its crop protection research data
SAN FRANCISCO and OXFORD, England, Dec. 17, 2019 /PRNewswire/ -- MoA Technology Ltd (MoA Tech) and Collaborative Drug Discovery, Inc (CDD) announced today that MoA Tech teams are successfully running CDD Vault, a comprehensive informatics platform for archiving, mining and analysing chemistry and...
2019-12-17 17:00
1330
Great Eastern Takaful Berhad partners DoctorOnCall to offer Harapan Trio customers revolutionary digital healthcare services
KUALA LUMPUR, Malaysia, Dec. 17, 2019 /PRNewswire/ -- After a successful launch of Harapan Trio Campaign inSeptember 2019, Great Eastern Takaful Berhad is now partnering online healthcare provider, DoctorOnCall to offer additional benefits to its Harapan Trio customers. Customers can now enjoy co...
2019-12-17 08:00
3849
TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure
NANJING, China, Dec. 16, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based inNanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for TT-00920, a novel ...
2019-12-17 08:00
1456
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
* Overall response rate (ORR) of 31% with 2.5 mg/kg regimen and no new safety signals in heavily pre-treated patient population who were refractory to an immunomodulatory drug and a proteasome inhibitor, and were refractory or intolerant to an anti-CD38 antibody * Data published in The Lancet...
2019-12-17 07:47
7620
UTSA Opens Call for Entries for $4 Million Oskar Fischer Prize to Expand Understanding and Explanation of Alzheimer's Disease
SAN ANTONIO, Dec. 17, 2019 /PRNewswire/ -- Today, The University of Texas at San Antonio (UTSA) announced that the official call for entries has opened for the Oskar Fischer Prize to expand the understanding and explanation of Alzheimer's disease. Entries for the prize can be submitted throughDec...
2019-12-17 00:05
1067
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement wi...
2019-12-16 18:33
6652
Ping An Good Doctor Launches Overseas Medical Service with Thailand's BDMS, Enabling "Face-to-face" Consultation with Top-tier Doctors for Users in the Comfort of Their Home
SHANGHAI, Dec. 16, 2019 /PRNewswire/ -- On 16 December, the world's leading healthcare ecosystem platform,Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; stock code:01833.HK) announced that the Company and Thailand's largest healthcare group Bangkok Dusit Medical Service...
2019-12-16 17:08
6997
HOYA Group PENTAX Medical Cleared CE Mark for DISCOVERY(TM), an AI Assisted Polyp Detector
TOKYO, Dec. 16, 2019 /PRNewswire/ -- PENTAX Medical, a division of the HOYA Group, announced that it has cleared CE mark for DISCOVERY™, an innovative Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination....
2019-12-16 16:00
1894
Ally Bridge Group Leads More Than US$140 million in Financings for Three New Medtech Investments
HONG KONG and NEW YORK, Dec. 16, 2019 /PRNewswire/ -- Ally Bridge Group ("ABG"), a leading global life science investment group, has announced that it recently led investments in three new medical technology companies. Each of the three companies is a commercial-stage, leading innovator re-settin...
2019-12-16 09:00
3626
etectRx Announces U.S. FDA Clearance of Novel Ingestible Event Marker
ID-Cap System Uses Advanced Wireless Technology to Reliably Track Ingestion Events GAINESVILLE, Florida, Dec. 16, 2019 /PRNewswire/ -- etectRx®, Inc. (etectRx), a privately-held digital health company, has announced U.S. Food and Drug Administration (FDA) clearance of its breakthrough patented i...
2019-12-16 07:06
1662
AT & IT China 2020, to be held alongside CPhI & P-MEC China 2020, will showcase Intelligent Pharma High-tech solutions
SHANGHAI, Dec. 13, 2019 /PRNewswire/ -- AT & IT China 2020, organized by Informa Markets andChina Chamber of Commerce for Import & Export of Medicines & Health Products and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., to take place at the Shanghai New Int...
2019-12-13 16:42
2799
Zurich Malaysia partners with DoctorOnCall to provide Malaysians a convenient way to manage their health
KUALA LUMPUR, Malaysia, Dec. 13, 2019 /PRNewswire/ -- Zurich Life Insurance Malaysia Berhad and Zurich Takaful Malaysia Berhad (Zurich Malaysia) have recently signed an agreement with leading online healthcare provider DoctorOnCall to extend complimentary* digital healthcare services to its new ...
2019-12-13 08:00
4663
Akkad Holdings Asia and FKS Group Announce Global Partnership
DETROIT, Dec. 13, 2019 /PRNewswire/ -- Akkad Holdings Asia, LLC and the FKS Group today announced a global strategic partnership, FKS Akkad Capital, LP. The partnership will combine Akkad Holdings Asia's expertise, proven entrepreneurial success and its exceptional network with the know-how, res...
2019-12-13 05:49
2614
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS
TAIPEI and SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492), a clinical stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced positive results from its Phase 1 trial of CX-5461. C...
2019-12-13 04:00
2422
Drug Manufacturers Eye Analytical Instrumentation to Reduce Operating Costs
SANTA CLARA, California, Dec. 12, 2019 /PRNewswire/ -- The total analytical instrumentation market in pharmaceuticals, biopharmaceuticals, and nutraceuticals generated revenues of $3.05 billion in 2018 and is expected to grow at aCAGR of 7.0% to touch $4.91 billion in 2025. Pharmaceuticals were t...
2019-12-12 23:11
1155
United Imaging's Artificial Intelligence Subsidiary Wins in Facebook AI Research & NYU School of Medicine Global Competition
HOUSTON, Dec. 12, 2019 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, followed a strong appearance at the annual meeting of the Radiological Society ofNorth America (RSNA) with a win in a competition jointly organized by Facebook AI Researc...
2019-12-12 21:00
1674
HemoCue AB, the Pioneer and Global leader in Hemoglobin (Hb) Point-of-care Testing (POCT) to Further Strengthen National Activities in the Combat against Anemia in India
HemoCue AB report fruitful discussions, continued support and new activities related to health initiatives, following the participation at the High-Level Business Delegation inNew Delhi and Mumbai, on December 2-4, 2019 STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- In 2019, Sweden and India celebrate ...
2019-12-12 16:11
891
World-class Performance with Assistance of Artificial Intelligence
STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- In the latest version of Ortoma Treatment Solution, OTS 4, Ortoma has introduced support of Artificial Intelligence. The system drastically reduces the time needed for pre-operatively planning of a hip implant in 3D, which has created a big interest for t...
2019-12-12 15:58
1284
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods ...
2019-12-12 14:47
3327
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
